（原标题：中慧生物-B(02627)旗下慧尔康欣®作为唯一疫苗入选国家医保创新药品初审名单） 集团的商品名为慧尔康欣的四价流感病毒亚单位疫苗于2023年5月获得中国国家药品监督管理局的新药 申请(NDA)批准，可用于三岁及以上人群(就含病毒株血凝素浓度而言规格为15μg/0.5ml)，为截至2025 年7月21日在中国获批的首款且唯一一款四价流感病毒亚单位疫苗，旨在针对两种甲型流感病毒(H1N1 和H3N2亚型)和两种乙型流感病毒(Yamagata和Victoria谱系)提供广泛保护。该产品在传统病毒裂解疫苗 的基础上进行重大升级，具有保护全面、组分抗原纯度高、不良反应风险低等优势。 智通财经APP讯，中慧生物-B(02627)发布公告，根据国家医疗保障局于2025年8月12日发布的公告，本 年度国家商业健康保险创新药品目录通过初步审查的名单中，包括唯一一款疫苗产品—四价流感病毒亚 单位疫苗。 ...

Core Viewpoint - Zhonghui Biotech-B (02627.HK) announced that its quadrivalent influenza virus subunit vaccine has been included in the preliminary review list of the national commercial health insurance innovative drug catalog, marking it as the only vaccine product in this year's list [1] Group 1: Product Approval and Features - The quadrivalent influenza virus subunit vaccine, marketed as Huiru Kangsxin, received new drug application (NDA) approval from the National Medical Products Administration of China in May 2023 [1] - This vaccine is approved for individuals aged three and above, with a specification of 15μg/0.5ml for the hemagglutinin concentration of the virus strains [1] - It is the first and only quadrivalent influenza virus subunit vaccine approved in China as of July 21, 2025, targeting two types of influenza A viruses (H1N1 and H3N2 subtypes) and two types of influenza B viruses (Yamagata and Victoria lineages) [1] Group 2: Advantages of the Vaccine - The product represents a significant upgrade over traditional virus split vaccines, offering comprehensive protection, high purity of component antigens, and a lower risk of adverse reactions [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 此為本公司刊發的自願公告。不能保證本集團最終能夠成功開發並推廣其四價流 感病毒亞單位疫苗至所有預期適用年齡群體。本公司股東及潛在投資者於買賣本 公司證券時務請審慎行事。 承董事會命 江蘇中慧元通生物科技股份有限公司 執行董事、董事長兼總經理 安有才先生 Ab&B Bio-Tech CO., LTD. JS 江蘇中慧元通生物科技股份有限公司 香港，2025年8月13日 （於中華人民共和國成立的股份有限公司） 於本公告日期，董事會成員包括：(i)執行董事安有才先生、李潤香女士及何一鳴 先生；(ii)非執行董事程千文先生、于建林先生及杜沐先生；及(iii)獨立非執行董 事李向明先生、李曉青女士及陳乘貝先生。 （股份代號：2627) 自願性公告 本公告乃由江蘇中慧元通生物科技股份有限公司（「本公司」，連同其附屬公司「本 集團」）自願刊發，旨在向本公司股東（「股東」）及潛在投資者提供有關本公司最新 發展之資料。 ...

Core Viewpoint - The successful IPO of Zhonghui Biotech-B (02627) on August 11, 2025, marked a significant event in the Hong Kong stock market, with the stock price soaring by 157.98% on its first day, setting a record for the highest first-day gain of a new stock in 2025 [1] Company Overview - Zhonghui Biotech is a domestic innovative vaccine company with two core products: the quadrivalent influenza virus subunit vaccine (brand name: Huiru Kexin) and an in-development lyophilized human rabies vaccine [1][2] - The quadrivalent influenza vaccine is the first and only one approved in China for individuals aged 3 and above, showing significant improvements over traditional vaccines [2] Financial Performance - The public offering phase saw 191,000 participants with an oversubscription rate of 4007 times, freezing over HKD 210 billion, making it the "super subscription king" of the year in the biotech sector [1] - Sales revenue for Huiru Kexin is projected to reach HKD 260 million in 2024, a nearly 400% increase from HKD 52.2 million in 2023 [2] Product Pipeline - In addition to the two core products, Zhonghui Biotech has 11 other vaccines in development, including a trivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine, creating a diverse product pipeline [3] Market Trends - The Chinese innovative drug market is experiencing rapid growth, with the proportion of innovative drug business development (BD) transactions increasing from 10.8% in 2015 to 52.5% by August 2023 [3] - The global human vaccine market is expected to grow from USD 37.2 billion in 2019 to USD 49.8 billion in 2024, with a compound annual growth rate (CAGR) of 8.0% [5] Strategic Initiatives - Zhonghui Biotech's fundraising plan includes over 10% of funds allocated for strategic acquisitions, particularly in Southeast Asia, to enhance local production capabilities [4] - The company is also benefiting from favorable policies supporting innovative drugs, as indicated by recent meetings held by the National Medical Insurance Administration [5] Investment Appeal - The company is viewed as a defensive asset against global uncertainties, with its innovative vaccine technology positioned to thrive amid public health challenges [6] - The Chinese human vaccine market is projected to grow from RMB 53.5 billion in 2019 to RMB 96.1 billion in 2024, indicating substantial market potential [6]

Core Viewpoint - The successful IPO of Zhonghui Biotech-B (02627) on August 11, 2025, marked a significant event in the Hong Kong stock market, with the stock price soaring by 157.98% on its first day, setting a record for the highest first-day gain of a new stock in 2025 [1] Company Overview - Zhonghui Biotech is an innovative vaccine company in China, with two core products: the quadrivalent influenza virus subunit vaccine (Huiruankangxin®) and an in-development lyophilized rabies vaccine [1][3] - The company has seen a substantial increase in valuation from 746 million yuan to 4.189 billion yuan through three rounds of financing prior to its IPO [1] Product Details - Huiruankangxin® is the first and only quadrivalent influenza virus subunit vaccine approved in China, showing a nearly 400% increase in sales revenue from 52.2 million yuan in 2023 to 260 million yuan in 2024 [2] - The rabies vaccine, developed using human diploid cells, is expected to be a safer alternative to traditional Vero cell-based vaccines, with Phase I clinical trials completed and Phase III trials planned for Q3 2025 [3] Market Potential - The global human vaccine market is projected to grow from $37.2 billion in 2019 to $49.8 billion by 2024, with a compound annual growth rate (CAGR) of 8.0% [5] - The Chinese human vaccine market is expected to grow from 535 billion yuan in 2019 to 961 billion yuan by 2024, with a CAGR of 12.4% [6] Strategic Initiatives - Zhonghui Biotech's fundraising plan includes over 10% of funds allocated for strategic acquisitions, with 63.6% focused on global registration of core products [4] - The company is expanding its international presence, with plans to register products in multiple countries, including Thailand, Uruguay, and Indonesia [2][4] Industry Context - The rise of innovative drugs in China is evident, with the share of China's innovative drug business development (BD) transactions increasing from 10.8% in 2015 to over 50% in 2023 [3] - The company is positioned to benefit from favorable policies supporting innovative drugs, as indicated by recent meetings held by the National Healthcare Security Administration [5]

Summary of Key Points Core Viewpoint - A total of 142 stocks reached their 52-week highs as of August 12, with notable performers including Yingmei Holdings (02028), Elite Group (01775), and Fuying Global Group (01620) achieving high rates of 164.89%, 84.78%, and 40.63% respectively [1]. Stock Performance - **Top Performers**: - Yingmei Holdings (02028) closed at 0.223 with a peak of 0.249, marking a 164.89% increase [1]. - Elite Group (01775) closed at 0.350 with a peak of 0.425, reflecting an 84.78% increase [1]. - Fuying Global Group (01620) closed at 0.180, reaching its peak at 0.180, showing a 40.63% increase [1]. - **Other Notable Stocks**: - Aoya Group (02425) increased by 34.36% [1]. - Fuyiy International Holdings (01470) saw a rise of 28.30% [1]. - Huajian Medical (01931) experienced a 27.58% increase [1]. 52-Week High Rankings - The ranking of stocks that reached their 52-week highs includes: - Yingmei Holdings (02028) at 164.89% [1]. - Elite Group (01775) at 84.78% [1]. - Fuying Global Group (01620) at 40.63% [1]. 52-Week Low Rankings - The report also highlights stocks that reached their 52-week lows, with notable declines including: - Jiadeng International Group (08153) at -15.25% [4]. - Kun Group (00924) at -12.86% [4]. - Zhongjia Guoxin (00899) at -10.00% [4].

Group 1 - The Hang Seng Index rose by 0.09%, gaining 22 points to close at 24,929 points, while the Hang Seng Tech Index fell by 0.39%. The morning trading volume in Hong Kong was HKD 110.2 billion [1] - Dairy stocks led the gains, with expectations that fertility subsidies will boost dairy product demand. Institutions noted that the meat and milk cycle is favorable for livestock companies. Notable stock performances include: Aoyuan Group up 35.62%, Modern Farming up 15%, and China Shengmu up 13% [1] - Hong Teng Precision (06088) saw a rise of over 7% due to the mass production ramp-up of its GB200 series products, while BYD Electronics (00285) increased by over 4% [1] - Zhonghui Biotechnology-B (02627) surged over 16% on its second day of trading, following a nearly 158% increase the previous day, with a total market capitalization exceeding HKD 15 billion [1] - Ping An Good Doctor (01833) rose by 5.6%, reporting significant achievements in its medical AI products and ongoing optimization of its business structure [1] - Huachen China (01114) increased by over 9%, with expected profit growth of 13% to 16% for the first half of the year [1] - Zhenjiu Lidu (06979) rose by over 8%, with institutions suggesting that policy variables are accelerating industry clearing, and performance bottoming is expected as early as the first half of next year [1] Group 2 - Lithium stocks fell in early trading, with strong expectations of a contraction in lithium supply. Analysts indicated that the overall demand increase for the second half of the year lacks imagination. Tianqi Lithium (09696) dropped by 8%, and Ganfeng Lithium (01772) fell by 5% [2]

Core Viewpoint - Zhonghui Biotech-B (02627) experienced a significant stock price increase, soaring nearly 158% on its debut and continuing to rise over 20% the following morning, with a current price of 39.72 HKD and a market capitalization exceeding 15 billion HKD [1] Company Overview - Zhonghui Biotech focuses on the research, manufacturing, and commercialization of vaccines [1] - The company has two core products: a quadrivalent influenza virus subunit vaccine (approved by the National Medical Products Administration for individuals aged three and above in May 2023, branded as Huiru Kangkang) and an in-development lyophilized human rabies vaccine, which is developed using human diploid cells and demonstrates good safety [1] - Additionally, Zhonghui Biotech is working on 11 other vaccine candidates [1] IPO Performance - The IPO public offering of Zhonghui Biotech was oversubscribed by over 4,000 times, with a total subscription amount exceeding 200 billion HKD, making it the "super subscription king" in the Hong Kong stock market's 18A biotech sector this year [1]

Core Viewpoint - Zhonghui Biotech-B (02627) has experienced a significant stock price increase since its listing, reflecting strong market interest and investor confidence in its vaccine development capabilities [1] Company Overview - Zhonghui Biotech focuses on the research, manufacturing, and commercialization of vaccines [1] - The company has two core products: a quadrivalent influenza virus subunit vaccine, approved for individuals aged three and above, and an in-development lyophilized human rabies vaccine [1] - Additionally, Zhonghui Biotech is working on 11 other vaccine candidates [1] Market Performance - The stock surged nearly 158% on its first day of trading and continued to rise over 20% the following morning, with a current price of 39.72 HKD [1] - The total market capitalization of Zhonghui Biotech has surpassed 15 billion HKD [1] - The IPO public offering was oversubscribed by over 4000 times, with total subscription amounts exceeding 200 billion HKD, making it the "super subscription king" in the Hong Kong biotech sector for 2023 [1]

中慧生物此次全球发行3344.26万股H股，最终发售价为12.90港元，处于发行价格区间的低位，总 募集金额约4.31亿港元。上市所募资金将主要用于其核心产品的开发及国内外注册；其他在研疫苗的开 发和注册；以及改进工艺及商业化能力等方面。 (责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 中慧生物盘初拉升，现涨超12%，报价37.5港元，该股昨日上市飙升158%。 | 02627 中慧生物-B | | | | --- | --- | --- | | 37.500 + +4.220 +12.68% | | 交易中 08/12 09:48 | | 六 2 日 日 中 自选 | | ● 快捷交易 | | 最高价 37.800 | 开盘价 34.000 | 成交量 77.56万 | | 最低价 34.000 | 昨收价 33.280 | 成交额 2772.16万 | | 平均价 35 ...